Details for New Drug Application (NDA): 215446
✉ Email this page to a colleague
NDA 215446 describes RADICAVA ORS, which is a drug marketed by Mitsubishi Tanabe and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. Additional details are available on the RADICAVA ORS profile page.
The generic ingredient in RADICAVA ORS is edaravone. Four suppliers are listed for this compound. Additional details are available on the edaravone profile page.
The generic ingredient in RADICAVA ORS is edaravone. Four suppliers are listed for this compound. Additional details are available on the edaravone profile page.
Summary for 215446
| Tradename: | RADICAVA ORS |
| Applicant: | Mitsubishi Tanabe |
| Ingredient: | edaravone |
| Patents: | 5 |
Suppliers and Packaging for NDA: 215446
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| RADICAVA ORS | edaravone | SUSPENSION;ORAL | 215446 | NDA | Mitsubishi Tanabe Pharma America, Inc. | 70510-2321 | 70510-2321-2 | 2 CARTON in 1 CARTON (70510-2321-2) / 1 KIT in 1 CARTON (70510-2321-1) * 1 BOTTLE in 1 KIT (70510-2323-1) / 35 mL in 1 BOTTLE |
| RADICAVA ORS | edaravone | SUSPENSION;ORAL | 215446 | NDA | Mitsubishi Tanabe Pharma America, Inc. | 70510-2322 | 70510-2322-1 | 1 KIT in 1 CARTON (70510-2322-1) * 50 mL in 1 BOTTLE (70510-2324-1) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SUSPENSION;ORAL | Strength | 105MG/5ML | ||||
| Approval Date: | May 12, 2022 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | May 12, 2025 | ||||||||
| Regulatory Exclusivity Use: | NEW PRODUCT | ||||||||
| Regulatory Exclusivity Expiration: | May 12, 2029 | ||||||||
| Regulatory Exclusivity Use: | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) | ||||||||
| Patent: | ⤷ Sign Up | Patent Expiration: | Nov 1, 2039 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
